Sorrento Therapeutics Inc (SRNE)

[vegasandre]

How SRNE beats the COVID virus:

presentation:

https://investors.sorrentotherapeutics.com/static-files/75caa2e3-2048-4bf9-b935-7bb8c24fb39a




Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
Highlights of the presentation include:

MultiValent COVID Vaccine candidate comprised of proprietary designer Spike-encoding mRNAs designed to elicit cellular and humoral immunity against the early WA-1 virus as well as the predominant variants of concern (VOCs), Alpha, Beta, Gamma, Delta, and Lambda.

mRNA construct engineered to remove a furin cleavage site in the native spike protein. This cleavage site could potentially lead to spike protein being cleaved off the cells expressing the protein and then entering the circulation.

Thermostable mRNA lipid nanoparticle (LNP) formulation that potentially allows for provision of vaccine doses without the need for frozen storage after time of manufacture, during transport and prior to dose administration.